Entries by Henrik Jungaberle

Psychedelics as Medicine: Expert Interview with Dr. Henrik Jungaberle in the “Psych Report 2021”

DO PSYCHEDELICS REALLY HAVE THE POWER TO DISRUPT HEALTHCARE? IF SO, HOW?

The Psychedelics as Medicine Report: Third Edition (2021) is an industry report outlet. It describes itself as “a premium business-to-business media and content platform for the psychedelic science and healthcare industry. Part of Psych Capital Plc.”. As such it tries to collect “consumer insights and market intelligence from experts and industry leaders, helping investors cut through the noise and identify real opportunities.”
Dr. Henrik Jungaberle has been interviewed for the report by Floris Wolswijk. Henrik is not involved with and has not been paid for the interview by either of the parties who produced or sponsored the report. His views are his own.

Special Issue of Pharmacopsychiatry on Psychedelics in Psychiatry 2021 – the characteristics of disruptive treatments

The July 2021 special issue of Psychopharmacology is dedicated to the renaissance of psychedelics in psychiatry that has occurred during the past couple of years. “Psychedelics in Psychiatry 2021” contains four interesting review articles on different aspects of its historic development and current research as treatment in mood disorders and its effects in psychotherapy.
Together with Gerhard Gründer Henrik Jungaberle has co-authored a paper on “The potential role of psychedelic drugs in mental health care of the future”.

Conference: INSIGHT 2021 – an invitation to Berlin. Psychedelic research, therapy and drug development in Berlin

At INSIGHT 2021, scientists and therapists, pharmaceutical industry and anthropology, philosophers, and chemists will come together to determine the potential place of LSD, psilocybin, DMT, MDMA, and other psychedelic substances in the treatment of mental disorders. In addition, we will discuss the use of non-pharmacological methods to alter and cultivate states of consciousness and all that it takes to build such unusual states of consciousness a legitimate and safe place in society.

Writing the histories of psychedelic research: Wirtschaftswoche on German LSD-Researcher Hanscarl Leuner

German journalist Marlene Halser on the LSD-researcher Hanscarl Leuner
“Psychedelic mushrooms are in demand on the stock market – this man paved the way for them” (Wirtschaftswoche)

For almost 30 years, Hanscarl Leuner treated people with LSD and psilocybin at the University Hospital in Göttingen. Substances in which highly valued start-ups are currently investing – while the German researcher has been relegated to the sidelines of society.”
… and a free link to “The History of Psychedelics in Psychiatry”

Radio: “”High sein” – Henrik Jungaberle on a new edition of the drug education book in Deutschlandfunk Corso

“For anyone who wants to get a differentiated picture”.
Alcohol, coke, pills – the list of available drugs is long, and so is the list of addictions. “Being High” is a handbook that casts a nuanced picture on drugs of all kinds. “We have a very dysfunctional relationship with the people who use them,” author Henrik Jungaberle told Dlf.

Henrik Jungaberle in a Corso conversation with Ulrich Biermann

Podcast: Drugs are the answer to what question after all? Henrik Jungaberle in Wieprechts Truths

Drugs are the answer to what questions yet the same?

In a conversation with scientist and drug expert Henrik Jungaberle, Volker Wieprecht rethinks his plan to celebrate his 75th birthday with an opium intoxication. Why actually drugs and if so, for what purpose?

Wieprecht’s Wahrheiten is a podcast for everyone who wants to explore (with him) the deeper meaning of life.

Podcast: Henrik in conversation with Darek Dwanda on values and programs of the MIND Foundation

Berlin’s MIND Foundation is one of Europe’s largest psychedelic therapy organizations with global aspirations. MIND has a range of amazing programs for therapists, academics, and anyone else interested in new psychedelic therapies. In this episode we discuss a range of issues including European psychedelic landscape, ethics of Psychedelic-Assisted Therapies, cultural issues, issues of growth, and many other issues related to healing with psychedelics.